Literature DB >> 3134393

Immunological and biological potencies of the different molecular species of gonadotrophins.

A Ulloa-Aguirre1, R Espinoza, P Damian-Matsumura, S C Chappel.   

Abstract

Pituitary gonadotrophins (follicle-stimulating hormone, FSH; luteinizing hormone, LH) exist in different molecular forms within the anterior pituitary gland and serum of several non-mammalian and mammalian species, including man. The number and relative abundance of each gonadotrophin species will depend on the specific technique utilized for their isolation, the tissue source and the physiological status of the donor. Intracellular FSH and LH from glands of rodents (hamsters and rats) and primates exhibit charge heterogeneity and therefore may be separated into several forms or iso-hormones by isoelectric focusing (IEF). These FSH and LH species differ from each other not only in their isoelectric point (pI) but also in their relative abundance, receptor binding activity, biological activity and plasma half-life. Almost all gonadotrophin species isolated from pituitary extracts have also been detected in vitro and in vivo as secreted forms. Less basic rodent LH and FSH forms exhibit low receptor binding and in-vitro biological activities; a similar trend is found in LH and FSH species isolated from glands of monkeys and humans. However, these relatively acidic isohormones have longer circulatory half-lives and higher in-vivo biological activities than less negatively charged forms. The overall pattern of charge heterogeneity of gonadotrophins varies according to the specific endocrine status of the donor. Sex steroid hormones (mainly oestrogens) and gonadotrophin-releasing hormone seem to act in concert at the pituitary level to influence the physicochemical and functional characteristics of gonadotrophins and therefore their biological expression at the target cell. The effects of these factors appear to be mediated through the incorporation of specific carbohydrate residues and/or degree of terminal sugar sulphation at co-post-translational levels. The first result of these complex interactions between the gonad and the hypothalamic-pituitary unit is the production and secretion of various types of gonadotrophin molecules in proportions according with the physiological requirements of the subject at a given time, to perform specific actions upon gonadal maturation and/or function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134393     DOI: 10.1093/oxfordjournals.humrep.a136734

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  11 in total

Review 1.  In vitro bioassays of follicle-stimulating hormone: methods and clinical applications.

Authors:  M Simoni; E Nieschlag
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

Review 2.  Glycosylation of pituitary hormones: a necessary and multistep control of biopotency.

Authors:  C Ronin
Journal:  Glycoconj J       Date:  1992-12       Impact factor: 2.916

3.  European collaborative study of luteinizing hormone assay: 1. Epitope specificity of luteinizing hormone monoclonal antibodies and surface mapping of pituitary and urinary luteinizing hormone.

Authors:  S Costagliola; P Niccoli; M Florentino; P Carayon
Journal:  J Endocrinol Invest       Date:  1994-06       Impact factor: 4.256

4.  European collaborative study of LH assay: 3. relationship of immunological reactivity, biological activity and charge of human luteinizing hormone.

Authors:  P Niccoli; S Costagliola; M C Patricot; B Mallet; M Benahmed; P Carayon
Journal:  J Endocrinol Invest       Date:  1996-05       Impact factor: 4.256

5.  Role of environmental conditions on the expression levels, glycoform pattern and levels of sialyltransferase for hFSH produced by recombinant CHO cells.

Authors:  W Chotigeat; Y Watanapokasin; S Mahler; P P Gray
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

6.  Molecular composition of two different batches of urofollitropin: analysis by immunofluorimetric assay, radioligand receptor assay and in vitro bioassay.

Authors:  M Simoni; G F Weinbauer; E Nieschlag
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

7.  Reduced FSH and LH action: implications for medically assisted reproduction.

Authors:  E Bosch; C Alviggi; M Lispi; A Conforti; A C Hanyaloglu; D Chuderland; M Simoni; N Raine-Fenning; P Crépieux; S Kol; V Rochira; T D'Hooghe; P Humaidan
Journal:  Hum Reprod       Date:  2021-05-17       Impact factor: 6.918

Review 8.  Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.

Authors:  Rogério de Barros F Leão; Sandro C Esteves
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

9.  Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review.

Authors:  Bernd Th Krause; Ralf Ohlinger; Annette Haase
Journal:  Biologics       Date:  2009-07-13

10.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.